Potential Combination Therapy Approaches with Ruxolitinib in Myelofibrosis
April 26th 2023A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.
Read More
Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC
2 Commerce Drive
Cranbury, NJ 08512